Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways by Clements, C et al.
RESEARCH ARTICLE
Presence and distribution of progerin in HGPS cells is
ameliorated by drugs that impact on the mevalonate
and mTOR pathways
Craig S. Clements . Mehmet U. Bikkul . Wendy Ofosu . Christopher Eskiw .
David Tree . Evgeny Makarov . Ian R. Kill . Joanna M. Bridger
Received: 7 February 2019 / Accepted: 29 March 2019 / Published online: 30 April 2019
 The Author(s) 2019
Abstract Hutchinson–Gilford progeria syndrome
(HGPS) is a rare, premature ageing syndrome in
children. HGPS is normally caused by a mutation in
the LMNA gene, encoding nuclear lamin A. The
classical mutation in HGPS leads to the production of
a toxic truncated version of lamin A, progerin, which
retains a farnesyl group. Farnesyltransferase inhibitors
(FTI), pravastatin and zoledronic acid have been used
in clinical trials to target the mevalonate pathway in
HGPS patients to inhibit farnesylation of progerin, in
order to reduce its toxicity. Some other compounds
that have been suggested as treatments include
rapamycin, IGF1 and N-acetyl cysteine (NAC). We
have analysed the distribution of prelamin A, lamin A,
lamin A/C, progerin, lamin B1 and B2 in nuclei of
HGPS cells before and after treatments with these
drugs, an FTI and a geranylgeranyltransferase inhi-
bitor (GGTI) and FTI with pravastatin and zoledronic
acid in combination. Confirming other studies pre-
lamin A, lamin A, progerin and lamin B2 staining was
different between control and HGPS fibroblasts. The
drugs that reduced progerin staining were FTI,
pravastatin, zoledronic acid and rapamycin. However,
drugs affecting the mevalonate pathway increased
prelamin A, with only FTI reducing internal prelamin
A foci. The distribution of lamin A in HGPS cells was
improved with treatments of FTI, pravastatin and
FTI ? GGTI. All treatments reduced the number of
cells displaying internal speckles of lamin A/C and
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lamin B2. Drugs targeting the mevalonate pathway
worked best for progerin reduction, with zoledronic
acid removing internal progerin speckles. Rapamycin
and NAC, which impact on the MTOR pathway, both
reduced both pools of progerin without increasing
prelamin A in HGPS cell nuclei.
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HGPS Hutchinson–Gilford progeria syndrome
ICMT Isoprenyl-cysteine-carboxy-
methyltransferase
IGF-1 Insulin-like growth factor 1
mTOR Mammalian target of rapamycin
ROS Reactive oxygen species
Introduction
The nuclear lamina underlying the inner nuclear
membrane, consists of separate mesh-works of class
V intermediate filament proteins known as nuclear
lamins (Aebi et al. 1986; de Leeuw et al. 2018). The
importance of a correctly structured lamina is borne
out by the comprehensive range of cellular functions
that it is involved with (Bridger et al. 2014). This range
includes structural support (Tokes and Clawson 1989;
Schäpe et al. 2009), transcriptional regulation (Andrés
and González 2009; Dechat et al. 2008), positioning of
nuclear pores (Al-Haboubi et al. 2011), DNA replica-
tion (Hutchison et al. 1994), nuclear envelope break-
down and reformation during mitosis (Gerace and
Blobel 1980) and organisation of the genome (Andrés
and González 2009; Meaburn et al. 2007), through
lamina associated domains (LADs) (Guelen et al.
2008). There are two types of lamins in animal cells,
A-type lamins which are well expressed in differen-
tiated cells following gastrulation (Broers et al. 1997),
and B-type lamins. Due to alternative splicing, the
lamin A gene generates several isoforms, including
lamin A, C, C2 and lamin AD10 (Cau et al. 2014; Luo
et al. 2014). On the other hand, the two B-type lamins,
B1 and B2, are expressed from genes located on
different chromosomes. Lamin B2 in particular is
present in the vast majority of cell types, with the
exception of hepatocytes, unlike lamin B1 which does
not appear to be expressed in muscle or connective
tissue in mammalian cells (Broers et al. 1997).
A-type and B-type lamins are initially expressed as
precursors in the cytosol and referred to as prelamins
(Beck et al. 1990). Although sharing similarities in
structure, analysis on Xenopus oocytes and mouse
cells demonstrated the two lamin sub-types are in fact
two classes of proteins which assemble independently
(Goldberg et al. 2008; Sullivan et al. 1999), and in
order to carry out their function a number of post-
translational modifications must be first completed.
All lamins possess an N-terminal ‘‘head’’ domain
and four central alpha-helices interspersed by linker
regions. Through this complex, denoted ‘‘rod
domain’’, lamins interact with one another and
assemble into the nuclear envelope. The terminal
portion of the protein is defined by a C-terminus
containing a -CAAX box motif, which is crucial to the
lamin’s functionality (Holtz et al. 1989; Vorburger
et al. 1989; Reddy and Comai 2012). Nuclear lamins
undergo, post-translational modifications that involve
the farnesylation of the cysteine belonging to the -
CAAX terminal box by the farnesyltransferase
enzyme (Sinensky et al. 1994). This enables incorpo-
ration of the proteins into the endoplasmic reticulum
(Bergo et al. 2002). This process is followed by a
proteolytic cleavage after the cysteine residue and a
successive carboxymethylation of the terminal part of
the compound, operated by the isoprenyL-cysteine-
carboxy-methyltransferase (ICMT) enzyme (Beck
et al. 1990). B-type lamins remain farnesylated and
localise to the inner nuclear envelope by lateral
diffusion through the lipid bilayer (Holmer and
Worman 2001). The mature version of lamin A is
produced by a second proteolytic cleavage catalysed
by the Zinc Metallo-Protease STE24 (ZMPSTE24)
(Freije et al. 1999), causing the deletion of 15 amino
acids, including the modified cysteine where the
farnesylation occurs. This allows the soluble protein
to be imported into nuclei through the nuclear pore
complexes (Cau et al. 2014).
Hutchinson–Gilford Progeria Syndrome (HGPS) is
a fatal premature ageing syndrome in children with an
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incidence rate of 1 in 8 million live births (Pollex and
Hegele 2004; Gonzalo et al. 2017). Affected individ-
uals usually die in their teens (Worman et al. 2010;
Gonzalo et al. 2017). The typical characteristics
presented with HGPS include short stature, full-body
alopecia, decreased joint mobility, lack of subcuta-
neous fat and muscle, osteolysis, micrognathia, and
coxa valga (de Paula Rodrigues et al. 2002; Merideth
et al. 2008). While there are a number of mutations in
different genes that can cause HGPS the most common
mutation associated with ‘‘classical’’ HGPS is caused
by a de novo mutation in the lamin A (LMNA) gene
(De Sandre-Giovannoli, et al. 2003; Eriksson, et al.
2003). Even though it is a silent mutation found at
codon 608 (G608G, GGC[GGT) of the gene, it leads
to the increased usage of a cryptic splice site. This
results in the deletion of 150 nucleotides from exon 11
of the lamin A transcript (Eriksson, et al. 2003) that
includes the ZMPSTE24 cleavage site for processing
the immature lamin A (Freije et al. 1999; Pendas et al.
2002). The aberrant splicing leads to the formation and
accumulation of a dominant negative pre-lamin protein
(Eriksson et al. 2003) which remains anchored to the
nuclear membrane, a property associated with B-type
lamins and not A-type. The failure of the mutant lamin
A protein to be cleaved results in a permanently
farnesylated toxic protein, termed ‘progerin’ (Yang
et al. 2005), that accumulates in the nuclear membrane.
This mechanism is thought to be the underlying cause
of premature aging in HGPS (Bridger and Kill 2004;
Columbaro et al. 2005). The nuclei of HGPS fibroblasts
develop a distorted shape, exhibiting blebs, herniations
and lobulations, as well as the formation of micronuclei
(Bridger and Kill 2004; Goldman et al. 2004; Paradisi
et al. 2005). Progerin has also been revealed in normal
aged cells both in vivo and in vitro, highlighting one of
the main correlations between HGPS and normal
ageing (Scaffidi and Misteli 2006). Indeed, various
forms of farnesylated lamin A are thought to be
involved in the ageing process (Reddy and Comai
2012; Cao et al. 2011; McClintock et al. 2007; Bonello-
Palot et al. 2014).
Therapeutic strategies for treating HGPS involve
blocking the farnesylation of progerin (Gordon et al.
2014, Varela et al. 2008) or the activation of pathways
that facilitate the removal/degradation of progerin
(Cao et al. 2011; Mendelsohn and Larrick 2011). One
option is to inhibit the synthesis of farnesyl precursors
through disruption of major biochemical pathways
responsible for its production, the mevalonate path-
way. Several drugs exist that inhibit this pathway at
several points blocking the farnesylation of progerin.
By inhibiting the farnesylation of progerin it is
believed to reduce the toxicity of the protein as it
would be unable to incorporate into and accumulate
within the nuclear envelope. FTIs are such drugs that
act on the mevalonate pathway and are being employed
as anti-cancer therapeutics since these drugs inhibit the
farnesylation of the ras protein, commonly mutated in
cancers (Sun et al. 1995). While studies have shown
that FTIs can restore nuclear shape initially in mouse
models of progeria (Yang et al. 2005), in human HGPS
fibroblasts (Glynn and Glover 2005) and in mesenchy-
mal stem cells (MSC) derived from HGPS iPS cells
(Blondel et al. 2014), deleterious effects of FTI
treatment have been noted. FTI treatment can lead to
the formation of abnormal donut-shaped nuclei (Ver-
straeten et al. 2011) and can redistribute normal A-type
lamins away from the inner nuclear envelope (Wang
et al. 2012). Furthermore, prelamin A has been shown
to be over-expressed and accumulate in MSC derived
from HGPS iPS cells (Blondel et al. 2014). Pravastatin
and zoledronic acid (an amino-bisphosphonate), which
inhibit the HMG-CoA reductase and FPP synthetase
enzymes of the mevalonate pathway respectively, have
been also been used as treatments for HGPS since
statins and amino-bisphosphonates have been demon-
strated to improve longevity in ZMPSTE24 deficient
mouse models (Varela et al. 2008). The effectiveness
of FTI alone and in a combination treatment with
pravastatin and zoledronic acid in restoring nuclear
shape has been previously shown in in vivo mouse
models (Wang et al. 2010).
Three clinical trials for HGPS sufferers were active
this decade. Firstly, a trial using lonafarnib (an FTI)
alone for 2 years was reported to have benefits for the
children in bone structure, vascular stiffness and
hearing (Gordon et al. 2014) and survival (Gordon
et al. 2018). A subsequent trial was a three drug
combination of lonafarnib, pravastatin and zoledronic
acid based in the United States at Children’s Hospital
Boston (Clinical trial ID: NCT00879034). This trial
has reported that using the two additional drugs have
resulted in an increase in bone mineral density
(Gordon et al. 2016). A trial using a two drug
combination of pravastatin and zoledronic acid based
in France at the Assistance Publique Hopitaux De
Marseille (Clinical trial ID: NCT00731016) for HGPS
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patients has concluded. The combination of a bispho-
sphonate and pravastatin have shown improvements in
skin ageing external markers i.e. wrinkles in one study
(Cantecor et al. 2013). We have found previously that
FTIs alone, and in combination with pravastatin and
zoledronic acid place chromosomes back into their
correct locations in interphase nuclei (Bikkul et al.
2018, Bridger et al. 2014) and that an active mech-
anism for their specific relocation is also restored with
FTI (Mehta et al. 2011).
FTI inhibition through farnesylation of progerin and
prelamin A can be made more efficient through the
additional use of geranylgeranyltransferase inhibitors
(GGTIs) (Varela et al. 2008). Geranylgeranyltransferase
adds a lipophilic geranylgeranyl moiety to proteins than
contain CAAX motifs (Yoshida et al. 1991). Other drugs
have also been presented as having the potential to treat
progeria patients and are going into trial for progeria,
such as the rapalogue of rapamycin, everolimus (Clin-
ical Trial ID NCT02579044). Rapamycin, a mechanistic
target of rapamycin (mTOR) inhibitor, has been shown
to decrease insoluble progerin aggregates within nuclei
of HGPS fibroblasts through autophagic degradation
(Cao et al. 2011, Cenni et al. 2011) and have an positive
effect on MSC derived from HGPS iPS cells by reducing
the number of progerin expressing cells (Blondel et al.
2014). Further, rapamycin has been demonstrated to
reduce nuclear blebbing in HGPS fibroblast cells
(Driscoll et al. 2012) and improve nuclear shape in
MSC derived from HGPS iPS cells in a quarter of the
population (Blondel et al. 2014). More clinically
relevant rapalogues such as temsirolimus and ever-
olimus generate a range of improvements in HGPS
cells; with temsirolimus reducing progerin levels,
increasing proliferation, correcting mis-shaped nuclei
and improving the fraction of DNA damage foci
(Gabriel et al. 2016). ZMPSTE24 (-/-) mice have
been shown to be deficient in insulin-like growth factor
1 (IGF-1) and exhibit elevated levels of growth hormone
(GH). Administering recombinant IGF-1 protein to the
mice restores the GH/IGF-1 balance and increases their
longevity (Marino et al. 2010). HGPS fibroblasts have
been shown to have DNA repair defects, exhibiting
elevated levels of DNA double stand breaks (DSB) (Liu
et al. 2005). This damage is thought to be due to the
generation of reactive oxygen species (ROS) (Pereira
et al. 2008). N-acetyl-L-cysteine (NAC) is a ROS
scavenger that has been shown to reduce the levels of
ROS-induced DSBs in HGPS fibroblasts (Richards et al.
2011). However, NAC is also an activator of the mTOR
pathway (Chen et al. 2014).
While extensive studies using proposed drugs for
HGPS treatment have been conducted using mouse
models, relatively few studies have used primary cells
to investigate their effect on the distribution of nuclear
proteins, such as lamins. The effect of drugs that do not
target the mevalonate pathway on lamins in HGPS
fibroblasts is largely unknown. To address this current
gap in knowledge, the purpose of this study was to test
whether or not the proposed drugs and combinations
of drugs used in clinical trials can improve the
distribution of nuclear lamins in HGPS fibroblasts.
We have found using careful analysis of indirect
immunofluorescent staining patterns, that drugs which
prevent farnesylation of progerin through the meval-
onate pathway and drugs the activate the mTOR
pathway restore the nuclear distribution and comple-
ment of nuclear lamins back to a normal level.
Materials and methods
Cell culture
The AG01972 primary HGPS cell line was obtained
from Coriell Cell Repositories (New Jersey, USA).
The 2DD normal dermal fibroblast cell line was used
as described previously (Bridger et al. 1993).
AG01972 cells were cultured in T75 tissue culture
treated flasks (Fisher, UK) containing Dulbecco’s
Minimum Essential Media ? Glutamax (Invitrogen,
UK), supplemented with 15% foetal calf serum and
1% penicillin/streptomycin (Invitrogen) in an humid-
ified, 37 C, 5% CO2/95% air incubator. The cells
were passaged twice weekly. Cells were plated at a
density of 2 9 105 into 9 cm dishes containing 13 mm
diameter glass coverslips.
Antibodies and drug treatments
The antibodies used in this investigation were anti-
prelamin A (SC-6214, goat polyclonal IgG, Santa
Cruz, USA) at a 1:50 dilution, anti-lamin A (AB8980,
mouse monoclonal IgG3, Abcam, UK) at a 1:50
dilution, anti-lamin A/C (NCL-LAM-A/C, mouse
monoclonal IgG2B, Leica Biosystems, Germany) at
a 1:100 dilution, anti-progerin (ALX-804-662-R200,
mouse monoclonal IgG1, Enzo Life Sciences, USA) at
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a 1:50 dilution, anti-lamin B1 (AB8982, mouse
monoclonal IgG1, Abcam, UK) at a 1:100 dilution
and anti-lamin B2 (AB8983, mouse polyclonal IgG1,
Abcam, UK) at a 1:100 dilution. The secondary
antibodies used were FITC conjugated donkey anti-
mouse IgG (715-095-150, Jackson Immunosearch,
USA) and FITC conjugated donkey anti-goat IgG
(705-095-147, Jackson Immunosearch, USA) at 1:50
dilution. The drugs used were FTI-277, pravastatin,
zoledronic acid, rapamycin, insulin-like growth factor
1, N-acetyl-L-cysteine and GGTI-2133, were obtained
from Sigma Aldrich, UK. Drugs were added to the
media and incubated for fixed periods of time. The
final concentration and duration of drug treatments
followed were extracted from previous studies and as
such relevant to whole organisms or other in vitro
studies: FTI-277 and GGTI-2133—2.5 lM for 48 h
(Kieran et al. 2007; Mehta et al. 2010), pravastatin and
zoledronic acid—1 lM for 24 h (Varela et al. 2008),
N-acetyl-L-cysteine—20 lM for 1 h (Richards et al.
2011), IGF1—50 ng ml-1 for 24 h (Marino et al.
2010) and rapamycin—10 nM for 24 h (Cao et al.
2011).
Indirect immunofluorescence
Cells grown on coverslips were washed three times in
PBS and then fixed with ice-cold methanol:acetone
(1:1). Cells were then further washed three times in
PBS. Primary antibodies were applied to the coverslip
for 1 h, and then washed in a PBS row. The secondary
antibodies are then applied for 1 h, followed by further
washing in a PBS row. The coverslips were then
mounted onto glass slides with Vectashield Mounting
Medium containing DAPI (Vector Labs). Nuclei were
imaged using an Olympus BX-41 fluorescence micro-
scope (Olympus Corporation, Japan) with an UPlanFl
9100/1.30 objective lens (Olympus Corporation,
Japan). Images were captured with Viewpoint GS
digital camera and SmartCapture 3 software for Apple
Mac for the same length of exposure (both Digital
Scientific UK).
Data analysis
The images of antibody stained nuclei were manually
scored for criteria. The number of nuclei exhibiting a
given pattern was expressed as a percentage of the
total number of nuclei scored in that analysis. Values
are expressed as averages ± SEM, and n represents
the number of experiments analysed. Individual
treatments were compared using two-way ANOVAs
with Tukey’s post hoc multiple comparison tests, and
significance was taken as P B 0.05. The level of
significance is indicated as: * P B 0.05, ** P B 0.01,
*** P B 0.001 and **** P B 0.0001. Analysis was
performed using Graphpad Prism 6.0 for Windows
package.
Results
Nuclear lamins are found at the nuclear periphery in a
rim subjacent to the inner nuclear membrane, but also
as internal speckle structures deep within nuclei. This
is true not only for lamin A (Bridger et al. 1993;
Goldman et al. 1992), but also prelamin A (Sasseville
and Raymond 1995), and even B-type lamins (Moir
et al. 1994) can be observed located within internal
foci. In this study, we have analysed nuclear lamin
presence and distribution before and after a panel of
single and combinatorial drug treatments in HGPS
primary fibroblasts. We defined a series of patterns for
the staining of both A-type and B-type lamins
including prelamin A and progerin to not only include
the nuclear periphery but also to take into consider-
ation internal lamin foci. Thus, these patterns are
described as four distinct sub-categories: (1) rim only,
(2) rim with internal speckles, (3) internal speckles
only and, (4) negative. For prelamin A the rim staining
has been sub-categorised into strong and weak to
differentiate between effects of different drugs.
Research looking at the distribution of nuclear lamins
in HGPS fibroblasts, including B-type lamins, has
been previously performed (Adam et al. 2013),
however only FTIs and GGTIs were studied. In this
study, we have used a much wider range of actual and
proposed drug treatments for HGPS to reveal their
effects on the lamin distribution in fibroblast nuclei.
Prelamin A distribution
To determine the impact of single and combinatorial
treatments of drugs on pre-lamin A distribution we
employed control and HGPS primary fibroblasts and
indirect immunofluorescence. In control fibroblasts it
was difficult to reveal any prelamin A staining since it
is processed rapidly and thus most of the cells appear
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negative (Figs. 1, 2, Supplementary Table 1). How-
ever, the untreated HGPS fibroblasts exhibit a majority
of cells with prelamin A internal speckles (55%) and a
weak rim staining in addition to internal speckles
(20%). These data suggest that in HGPS fibroblasts,
prelamin A is not only accumulating at foci within the
nucleoplasm but also additionally at the nuclear rim.
Following FTI-277 treatment (Fig. 2a), there is a
significant reduction (55%[ 3.5%) in the proportion
of HGPS cells displaying only internal speckles of
prelamin A compared to the untreated HGPS fibroblast
cells. Conversely, there is a significant increase in the
proportion of cells displaying a strong nuclear rim
staining with internal foci (82%) compared to the
untreated HGPS fibroblast (1.8%). These data are in
agreement with similar analyses suggesting that
prelamin A staining intensifies at the nuclear rim in
HGPS fibroblasts in response to FTI treatment (Adam
et al. 2013). Following pravastatin treatment (Fig. 2b),
there is a significant reduction in the fraction of cells
displaying internal speckles only (13%) compared to
the untreated HGPS fibroblasts (43%). There is also a
significant increase in the fraction of HGPS cells
displaying a weak rim and internal speckles (58%)
compared to the untreated HGPS fibroblast cells
(20%) indicating that prelamin A is again re-localising
to the nuclear rim. Following zoledronic acid treat-
ment (Fig. 2c), there is a significant reduction in the
fraction of cells displaying intranuclear speckles
(13%) compared to the untreated HGPS fibroblast
Fig. 1 Representative images of prelamin A staining of HGPS
fibroblast nuclei. Representative images of HGPS nuclei fixed
with methanol:acetone and stained using a prelamin A primary
antibody and a FITC-conjugated secondary antibody. Images
captured at 9100 magnification using an Olympus BX-41
fluorescence microscope with an UPlanFl 9100/1.30 objective
lens (Olympus Corporation, Japan). Images were captured with
Viewpoint GS digital camera and SmartCapture 3 software for
Apple Mac (both Digital Scientific UK). The treatments are
shown as a untreated 2DD b untreated AG01972, c AG01972
with FTI-277 (2.5 lM for 24 h), d AG01972 with pravastatin
(1 lM for 24 h), e AG01972 with zoledronic acid (1 lM for
24 h), f AG01972 with rapamycin (10 nM for 24 h), g AG01972
with insulin-like growth factor 1 (50.0 ng ml-1 for 24 h),
h AG01972 with N-acetyl-L-cysteine (20 lM for 1 h),
i AG01972 with FTI-277 and GGTI-2133 (both 2.5 lM for
24 h), j AG01972 with pravastatin and zoledronic acid (both
1 lM for 24 h) and k AG01972 with FTI-277 (2.5 lM for 24 h),
pravastatin and zoledronic acid (both 1 lM for 24 h). Scale
bar = 10 lM
cFig. 2 Scoring of prelamin A stained AG01972 fibroblasts
after drug treatment. 2DD and AG01972 nuclei fixed with
methanol:acetone and stained using prelamin A primary
antibodies and FITC-conjugated secondary antibodies were
scored by eye using an Olympus BX-41 fluorescence micro-
scope with an UPlanFl 9100/1.30 objective lens (Olympus
Corporation, Japan). The scoring patterns used for the analysis
were negative, speckles, aggregates, weak rim and speckles, and
strong rim and speckles. Scoring results for the treatments are
shown as a FTI-277 (2.5 lM for 24 h), b pravastatin (1 lM for
24 h), c zoledronic acid (1 lM for 24 h), d rapamycin (10 nM
for 24 h), e insulin-like growth factor 1 (50.0 ng ml-1 for 24 h),
f N-acetyl-L-cysteine (20 lM for 1 h), g FTI-277 and GGTI-
2133 (both 2.5 lM for 24 h), h pravastatin and zoledronic acid
(both 1 lM for 24 h) and i FTI-277 (2.5 lM for 24 h),
pravastatin and zoledronic acid (both 1 lM for 24 h). Error
bars are Standard error of the mean (SEM)
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cells (43%). However, in a similar result as that
revealed with pravastatin treatment, there is a signif-
icant increase in the proportion of weak rim and
speckle staining cells (52%) compared to the untreated
HGPS fibroblast cells (20%). Following rapamycin
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the fraction of cells displaying internal speckles (17%)
compared to the untreated HGPS fibroblasts (43%).
There is also highly significant increase in the fraction
of cells with negative staining for prelamin A (71%)
compared to the untreated HGPS fibroblast cells
(23%), bringing the overall results for rapamycin
treatment with respect to prelamin A in line with those
of the control fibroblasts.
Following IGF-1 treatment (Fig. 2e), there is also
significant reduction in the proportion of cells reveal-
ing internal prelamin A speckles (7%) compared to the
untreated HGPS fibroblast cells (43%). Conversely,
there was also a significant increase in the proportion
of negative staining cells (55%) compared to the
untreated HGPS fibroblast cells (23%). Similarly to
rapamycin, the results indicate a pattern more consis-
tent to that of the control cells. Following NAC
treatment (Fig. 2f), there was again a significant
reduction in the proportion of cells displaying internal
speckles (15%) compared to the untreated HGPS
fibroblast cells (43%). There was also a significant
increase in the proportion of negative staining (55%)
compared to the untreated HGPS fibroblast cells
(23%). Following combinatorial treatment with FTI-
277 and GGTI-2133 (Fig. 2g), there was a significant
reduction in the proportion of HGPS cells displaying
internal speckles (1%). There was also a significant
increase in the proportion of strong rim and speckles
(69%) compared to the untreated HGPS fibroblast
cells (1.8%). This result is very similar to that of FTI-
277 treatment alone, where there is an accumulation of
prelamin A at the nuclear rim following treatment.
There was a significant reduction in the proportion of
cells with speckles following combinatorial treatment
of pravastatin and zoledronic acid (4%) (Fig. 2 h)
compared to the untreated HGPS fibroblasts. Contrary
to this, there was a significant increase in the
proportion of weak rim and speckles (59%) compared
to the untreated HGPS fibroblast controls (21%). The
result is very similar to that of pravastatin and
zoledronic acid treatments alone. Following the com-
binatorial treatment of FTI-277, pravastatin and
zoledronic acid (Fig. 2i), there was a significant
reduction in the fraction of HGPS cells displaying
internal speckles (0.1%) and negative staining (3%)
compared to the untreated HGPS fibroblast cells.
However, there is also a significant increase in the
proportion of strong rim and speckles (85%) compared
to the untreated HGPS fibroblast cells. This result
resembles that of FTI-277 alone, and combination
treatment of FTI-277 and GGTI-2133. In general, it
was further noted that the addition of FTIs in any
combination led to a characteristic dull prelamin A
stain across the nucleoplasm (Fig. 1c, i, k). This was
also present, but to a lesser extent, when using
pravastatin and zoledronic acid (Fig. 1d, e, j). Taken
together the data generated by these analyses reveal
that Rapamycin, IGF1 and NAC would be the drugs
that bring the HGPS cells closer to control cells by
increasing the proportion of prelamin A negative cells.
The drugs that inhibit the farnesylation create HGPS
cells with increased staining at the nuclear envelope
and with internal foci.
Lamin A distribution
In terms of lamin A distribution within nuclei (Figs. 3,
4), untreated HGPS fibroblasts exhibited a significant,
substantial reduction in the proportion of cells where
rim staining (0.2%) and rim and speckles staining was
observed (0.0%) compared to fibroblast controls (81%
and 19%, respectively). Untreated HGPS fibroblasts in
this study predominantly exhibited negative staining
for lamin A (94%) with some near negative, barely
detectable staining (6%). Upon FTI-277 treatment
(Fig. 4a), the fraction of HGPS cells with rim staining
of mature lamin A (36%) and rim and speckles staining
(59%) is significantly increased compared to untreated
HGPS fibroblasts. The proportion of nuclei exhibiting
negative staining (2%) is also significantly less than
untreated HGPS fibroblasts (94%). Taken together,
these data suggest that FTI rescues lamin A distribution
in HGPS fibroblasts. Upon pravastatin treatment
(Fig. 4b), the proportion of HGPS cells with rim
staining (50%) and rim and speckles staining (44%) is
also significantly increased compared to untreated
HGPS fibroblasts. In addition, the proportion of nuclei
exhibiting negative staining (2%) is also significantly
less than untreated HGPS fibroblasts. Taken together,
these data reveal that pravastatin also rescues lamin A
distribution in HGPS fibroblasts. However, upon
zoledronic acid treatment (Fig. 4c) there is a much
less increase in the rim and rim and speckle staining
fractions in addition to a large number of cells still
showing no staining (67%), indicating that zoledronic
acid does not significantly alter the lamin A distribu-
tion in HGPS fibroblasts. This is also seen in the HGPS
cells treated with zoledronic acid in combination with
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FTI and pravastatin (Fig. 4h, i). In addition, rapamycin
treatment (Fig. 4d) had no impact on the fraction of
lamin A negative cells (94%). With IGF-1 treatment
(Fig. 4e), again, there is a complete absence of both rim
staining and rim and speckles staining, similar to
untreated HGPS fibroblasts however, the proportion of
nuclei exhibiting negative staining (70%) is still high
but is significantly less than untreated HGPS fibrob-
lasts (94%). Together, these data suggest that IGF1
seems to affect the lamin A distribution in HGPS
fibroblasts, but does not constitute a full rescue of the
protein to the nuclear envelope. Upon NAC treatment
(Fig. 4f), the proportion of cells with rim staining
(16%) is significantly increased compared to untreated
HGPS fibroblasts and the proportion of nuclei exhibit-
ing negative lamin A staining (68%) is significantly
less than untreated HGPS fibroblasts but again is still
high. These data reveal that NAC seems to have a
positive affect the lamin A distribution in HGPS
fibroblasts, but does not constitute a full rescue of the
protein to the nuclear envelope.
Upon combination treatment of FTI-277 and
GGTI-2133 (Fig. 4g), the proportion of cells with
both rim staining (13%) and rim and speckles staining
(82%) is significantly increased. The fraction of nuclei
exhibiting negative staining (2%) is significantly less
than HGPS fibroblasts. Upon combination treatment
of pravastatin and zoledronic acid (Fig. 4h), both the
rim staining (7%) and rim and speckles fractions (9%)
are low, similar to untreated HGPS fibroblasts.
However, the proportion of nuclei exhibiting negative
staining (75%) is still high but significantly altered.
Upon combination treatment of FTI-277, pravastatin
and zoledronic acid (Fig. 4i), rim staining cells (11%)
are significantly increased compared to HGPS fibrob-
lasts and the proportion of HGPS cells. The proportion
of nuclei exhibiting negative staining (67%) is signif-
icantly decreased compared to untreated HGPS
fibroblasts (94%). In summary zoledronic acid seems
to prevent a rescue of lamin A presence by FTI and
pravastatin when used in combination.
Lamin A/C distribution
In terms of anti-lamin A/C distribution within nuclei
(Figs. 5, 6), untreated HGPS fibroblasts exhibited a
Fig. 3 Representative images of lamin A staining of HGPS
fibroblast nuclei. Representative images of HGPS nuclei fixed
with methanol:acetone and stained using a lamin A specific
primary antibody and a FITC-conjugated secondary antibody.
Images captured at 9100 magnification using an Olympus BX-
41 fluorescence microscope with an UPlanFl 9100/1.30
objective lens (Olympus Corporation, Japan). Images were
captured with a Viewpoint GS digital camera and SmartCapture
3 software for Apple Mac (both Digital Scientific UK). The
treatments are shown as a) untreated 2DD b untreated AG01972,
c AG01972 with FTI-277 (2.5 lM for 24 h), d AG01972 with
pravastatin (1 lM for 24 h), e AG01972 with zoledronic acid
(1 lM for 24 h), f AG01972 with rapamycin (10 nM for 24 h),
g AG01972 with insulin-like growth factor 1 (50.0 ng ml-1 for
24 h), h AG01972 with N-acetyl-L-cysteine (20 lM for 1 h),
i AG01972 with FTI-277 and GGTI-2133 (both 2.5 lM for
24 h), j AG01972 with pravastatin and zoledronic acid (both
1 lM for 24 h) and k AG01972 with FTI-277 (2.5 lM for 24 h),
pravastatin and zoledronic acid (both 1 lM for 24 h). Scale
bar = 10 lM
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Fig. 4 Scoring of lamin A stained AG01972 fibroblasts after
drug treatment. 2DD and AG01972 nuclei fixed with
methanol:acetone and stained using specific lamin A primary
antibodies and FITC-conjugated secondary antibodies were
scored by eye using an Olympus BX-41 fluorescence micro-
scope with an UPlanFl 9100/1.30 objective lens (Olympus
Corporation, Japan). The scoring patterns used for the analysis
were rim, rim and speckles, speckles, and negative. Scoring
results for the treatments are shown as a FTI-277 (2.5 lM for
24 h), b pravastatin (1 lM for 24 h), c zoledronic acid (1 lM
for 24 h), d rapamycin (10 nM for 24 h), e insulin-like growth
factor 1 (50.0 ng ml-1 for 24 h), f N-acetyl-L-cysteine (20 lM
for 1 h), g FTI-277 and GGTI-2133 (both 2.5 lM for 24 h),
h pravastatin and zoledronic acid (both 1 lM for 24 h) and
i FTI-277 (2.5 lM for 24 h), pravastatin and zoledronic acid
(both 1 lM for 24 h). Error bars are SEM
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significantly reduced proportion of rim only staining
in cells (9%) compared to the control fibroblasts
(87%). Furthermore, the untreated HGPS fibroblasts
have a significantly higher fraction of cells that display
internal speckles in addition to a rim stain for A-type
lamins (85%) compared to control fibroblasts (13%).
However, upon treatment with all the drugs and
combinations (Fig. 6), the proportion of rim only
staining for HGPS fibroblasts is significantly increased
compared to untreated HGPS controls (38–83%) with
IGF1, NAC and FTI ? GGTI having the best effect
and zoledronic acid the lesser effect. In addition, the
proportion of HGPS cells with rim and speckle
staining was significantly reduced (21–68%), again
with zoledronic acid being the drug that affected the
HGPS cells the least, implying that the presence of
zoledronic acid is inhibiting rescue. The drug treat-
ments that bring the HGPS cells closest to the control
fibroblasts are IGF-1 (Fig. 6e), NAC (Fig. 6f), FTI ?
GGTI (Fig. 6g).
Progerin distribution
Using an antibody specific for progerin (Fig. S1), the
toxic truncated form of lamin A found in HGPS cells,
reveals that most of the untreated HGPS fibroblasts
exhibited progerin both at the rim with internal
speckles but also 54% of cells with only internal
accumulations of progerin. Interestingly, the control
fibroblasts do not exhibit any staining of progerin at
the nuclear edge but 1% of the cells contain progerin
within internal speckles. These observations provide
further evidence that progerin is produced by cells
derived from healthy individuals (Figs. 7, 8). A
number of the treatments do not reduce the fraction
of cells with internal speckles of progerin i.e. FTI
alone, pravastatin alone, rapamycin, IGF1, pravastatin
and zoledronic acid in combination. However, the
fraction of negative cells with respect to progerin
staining is significantly increased from 12% for
untreated HGPS cells for treatments with FTI (43%),
pravastatin (31%), zoledronic acid (49%), rapamycin
(47%), NAC (33%), pravastatin and zoledronic acid
together (37%). This increase in negative cells seems
Fig. 5 Representative images of lamin A/C staining of HGPS
fibroblast nuclei. Representative images of HGPS nuclei fixed
with methanol:acetone and stained using a lamin A/C primary
antibody and a FITC-conjugated secondary antibody. Images
captured at 9100 magnification using an Olympus BX-41
fluorescence microscope with an UPlanFl 9100/1.30 objective
lens (Olympus Corporation, Japan). Images were captured with
a Viewpoint GS digital camera and SmartCapture 3 software for
Apple Mac (both Digital Scientific UK). The treatments are
shown as a untreated 2DD b untreated AG01972, c AG01972
with FTI-277 (2.5 lM for 24 h), d AG01972 with pravastatin
(1 lM for 24 h), e AG01972 with zoledronic acid (1 lM for
24 h), f AG01972 with rapamycin (10 nM for 24 h), g AG01972
with insulin-like growth factor 1 (50.0 ng ml-1 for 24 h),
h AG01972 with N-acetyl-L-cysteine (20 lM for 1 h),
i AG01972 with FTI-277 and GGTI-2133 (both 2.5 lM for
24 h), j AG01972 with pravastatin and zoledronic acid (both
1 lM for 24 h) and k AG01972 with FTI-277 (2.5 lM for 24 h),
pravastatin and zoledronic acid (both 1 lM for 24 h). Scale
bar = 10 lM
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to be due to the loss of progerin at the nuclear envelope
since these staining fractions reduce with all these
drug treatments, apart from zoledronic acid and NAC
where the cells displaying only internal speckles are
significantly reduced to 12 and 16%, respectively from
54%. IGF1 and combination treatment of FTI,
pravastatin and zoledronic acid do not elicit any
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distribution. The drugs that work the best in this
analysis are FTI and rapamycin creating the highest
proportion of negative cells for HGPS cells.
Lamin B1 and B2 distribution
To determine the impact of our outlined drug
treatments on lamin B1 and B2 distribution, we
repeated the analysis of treated and untreated HGPS
fibroblasts following indirect immunofluorescence
with specific antibodies to the two B-type lamins.
No significant changes in lamin B1 distribution was
observed for any of the conditions outlined within our
study (Fig. 9), indicating an independence of lamin
B1. The majority of control fibroblasts have a definite
rim stain of lamin B2 with some internal speckles
(89%) (Fig. 10). Untreated HGPS fibroblasts on the
other hand exhibit significantly lower fraction of cells
with rim and speckles staining (39%). In addition,
untreated HGPS fibroblasts exhibit significantly
higher proportion of speckles only staining (31%)
and as well as negative staining (18%). All the drug
treatments improved the HGPS cells with respect to
lamin B2 by exhibiting a reduction in the fraction of
lamin B2 speckle-only HGPS cells and increasing the
fraction of cells with both a lamin B2 rim and internal
foci, resembling the distribution observed in control
fibroblasts (Fig. 11).
bFig. 6 Scoring of lamin A/C stained AG01972 fibroblasts after
drug treatment. 2DD and AG01972 nuclei fixed with
methanol:acetone and stained using lamin A/C primary
antibodies and FITC-conjugated secondary antibodies were
scored by eye using an Olympus BX-41 fluorescence micro-
scope with an UPlanFl 9100/1.30 objective lens (Olympus
Corporation, Japan). The scoring patterns used for the analysis
were rim, rim and speckles, speckles, and negative. Scoring
results for the treatments are shown as a FTI-277 (2.5 lM for
24 h), b pravastatin (1 lM for 24 h), c zoledronic acid (1 lM
for 24 h), d rapamycin (10 nM for 24 h), e insulin-like growth
factor 1 (50.0 ng ml-1 for 24 h), f) N-acetyl-L-cysteine (20 lM
for 1 h), g FTI-277 and GGTI-2133 (both 2.5 lM for 24 h),
h pravastatin and zoledronic acid (both 1 lM for 24 h) and
i FTI-277 (2.5 lM for 24 h), pravastatin and zoledronic acid
(both 1 lM for 24 h). Error bars are SEM
Fig. 7 Representative images of progerin staining of HGPS
fibroblast nuclei. HGPS nuclei fixed with methanol:acetone
stained using a progerin primary antibody and a FITC-
conjugated secondary antibody. Images captured at 9100
magnification using an Olympus BX-41 fluorescence micro-
scope with an UPlanFl 9100/1.30 objective lens (Olympus
Corporation, Japan). Images were captured with a Viewpoint GS
digital camera and SmartCapture 3 software for Apple Mac
(both Digital Scientific UK). The treatments are shown as
a untreated 2DD b untreated AG01972, c AG01972 with FTI-
277 (2.5 lM for 24 h), d AG01972 with pravastatin (1 lM for
24 h), e AG01972 with zoledronic acid (1 lM for 24 h),
f AG01972 with rapamycin (10 nM for 24 h), g AG01972 with
insulin-like growth factor 1 (50.0 ng ml-1 for 24 h), hAG01972
with N-acetyl-L-cysteine (20 lM for 1 h), i AG01972 with FTI-
277 and GGTI-2133 (both 2.5 lM for 24 h), j AG01972 with
pravastatin and zoledronic acid (both 1 lM for 24 h) and
k AG01972 with FTI-277 (2.5 lM for 24 h), pravastatin and
zoledronic acid (both 1 lM for 24 h). Scale bar = 10 lM
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Discussion
The goal of this investigation was to assess the effects
of different drugs on nuclear lamin distribution in
HGPS fibroblasts, with the aim to reveal drug(s) or
combinations of drugs that could generate distribution
patterns within HGPS cells that most resemble
patterns within normal control fibroblasts. Fibroblasts
were grown in the presence of drugs and combinations
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clinic to treat HGPS. Furthermore, drugs that have
been suggested as potential treatments were also
investigated. The efficacy of proposed drug treatments
for HGPS, up until recently, focused on nuclear shape
since drugs in development for HGPS have been
demonstrated to improve the morphology of the
misshapen HGPS (Toth et al. 2005, Wang et al.
2010, Cao et al. 2011). This is a simple assay and does
not inform entirely about other issues within nuclei
that are affected by the presence of progerin, such as
genome behaviour (Goldman et al. 2002, 2004;
Meaburn et al. 2005, 2007; Mehta et al. 2011; Bikkul
et al. 2018), DNA repair and replication (Richards
et al. 2011; Bikkul et al. 2018) and the presence and
distribution of nuclear structures (Mehta et al. 2010).
More importantly, many HGPS cells in culture,
especially at early passage, do not have misshapen
nuclei. They have normal ellipsoid shape nuclei
(Bridger and Kill 2004; Mehta et al. 2010). This study
assesses the presence and distribution of six nuclear
lamin proteins using nine different drug regimes.
FTIs, statins and bisphosphonates are intended to
target progerin toxicity by preventing farnesylation
through the mevalonate pathway and thus prevent its
accumulation in the nuclear membrane. However,
farnesylation is an important, normal biological pro-
cess that modifies a number of proteins, including
prelamin A. In this study we found that FTI, pravas-
tatin and zoledronic acid did indeed bring about a
significant increase in the fraction of cells negative for
progerin, with FTI, pravastatin and zoledronic acid, in
bFig. 8 Scoring of progerin stained AG01972 fibroblasts after
drug treatment. 2DD and AG01972 nuclei fixed with
methanol:acetone and stained using progerin primary antibodies
and FITC-conjugated secondary antibodies were scored by eye
using an Olympus BX-41 fluorescence microscope with an
UPlanFl 9100/1.30 objective lens (Olympus Corporation,
Japan). The scoring patterns used for the analysis were rim,
rim and speckles, speckles, and negative. Scoring results for the
treatments are shown as a FTI-277 (2.5 lM for 24 h),
b pravastatin (1 lM for 24 h), c zoledronic acid (1 lM for
24 h), d rapamycin (10 nM for 24 h), e insulin-like growth
factor 1 (50.0 ng ml-1 for 24 h), f N-acetyl-L-cysteine (20 lM
for 1 h), g FTI-277 and GGTI-2133 (both 2.5 lM for 24 h),
h pravastatin and zoledronic acid (both 1 lM for 24 h) and
i FTI-277 (2.5 lM for 24 h), pravastatin and zoledronic acid
(both 1 lM for 24 h). Error bars are SEM
Fig. 9 Representative images of Lamin B1 staining of HGPS
fibroblast nuclei. HGPS nuclei fixed with methanol:acetone and
stained using lamin B1 primary antibodies and FITC-conjugated
secondary antibodies. Images captured at 9100 magnification
using an Olympus BX-41 fluorescence microscope with an
UPlanFl 9100/1.30 objective lens (Olympus Corporation,
Japan). Images were captured with a Viewpoint GS digital
camera and SmartCapture 3 software for Apple Mac (both
Digital Scientific UK). The treatments are shown as a untreated
2DD b untreated AG01972, c AG01972 with FTI-277 (2.5 lM
for 24 h), d AG01972 with pravastatin (1 lM for 24 h),
e AG01972 with zoledronic acid (1 lM for 24 h), f AG01972
with rapamycin (10 nM for 24 h), g AG01972 with insulin-like
growth factor 1 (50.0 ng ml-1 for 24 h), h AG01972 with N-
acetyl-L-cysteine (20 lM for 1 h), i AG01972 with FTI-277 and
GGTI-2133 (both 2.5 lM for 24 h), j AG01972 with pravastatin
and zoledronic acid (both 1 lM for 24 h) and k AG01972 with
FTI-277 (2.5 lM for 24 h), pravastatin and zoledronic acid
(both 1 lM for 24 h). Scale bar = 10 lM
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combination, most effective. However, we also
observed cells that had progerin within the nucleo-
plasm in speckles and that the fraction of these cells
did not change with FTI and pravastatin. This could
imply that there are two populations of progerin, one at
the nuclear envelope and one in the nuclear interior. At
present, it is not possible to comment whether one
population is more deleterious to the cell than the
other; since progerin at the nuclear envelope probably
causes mitotic catastrophe and create issues with
chromatin organisation; whereas the internal popula-
tion may affect transcription, DNA replication and
repair (Bridger and Kill 2004) and nucleolar structure
(Mehta et al. 2010). Two drugs that worked well for
HGPS and reduced the fraction of cells displaying
both a progerin rim and internal foci were zoledronic
acid and NAC, with zoledronic acid superior to NAC
with respect to the number of progerin negative cells it
generated. What was interesting in our study with
respect to progerin staining was that the combinations
of drugs did not perform better than their solo
counterparts, indeed sometimes worse. It should be
noted however that FTI ? GGTI did reduce the
fraction of cells displaying progerin speckles only.
FTI and pravastatin also performed well separately by
restoring normal lamin A staining to the HGPS
cultures which were mostly negative before treatment.
NAC and FTI ? GGTI again also restored normal
lamin A staining. This could explain why chromosome
Fig. 10 Representative images of Lamin B2 staining of HGPS
fibroblast nuclei. HGPS nuclei fixed with methanol:acetone and
stained using lamin B2 primary antibodies and FITC-conjugated
secondary antibodies. Images captured at 9100 magnification
using an Olympus BX-41 fluorescence microscope with an
UPlanFl 9100/1.30 objective lens (Olympus Corporation,
Japan). Images were captured with a Viewpoint GS digital
camera and SmartCapture 3 software for Apple Mac (both
Digital Scientific UK). The treatments are shown as a untreated
2DD b untreated AG01972, c AG01972 with FTI-277 (2.5 lM
for 24 h), d AG01972 with pravastatin (1 lM for 24 h),
e AG01972 with zoledronic acid (1 lM for 24 h), f AG01972
with rapamycin (10 nM for 24 h), g AG01972 with insulin-like
growth factor 1 (50.0 ng ml-1 for 24 h), h AG01972 with N-
acetyl-L-cysteine (20 lM for 1 h), i AG01972 with FTI-277 and
GGTI-2133 (both 2.5 lM for 24 h), j AG01972 with pravastatin
and zoledronic acid (both 1 lM for 24 h) and k AG01972 with
FTI-277 (2.5 lM for 24 h), pravastatin and zoledronic acid
(both 1 lM for 24 h). Scale bar = 10 lM. Scale bar = 10 lM
cFig. 11 Scoring of Lamin B2 stained AG01972 fibroblasts
after drug treatment. 2DD and AG01972 nuclei fixed with
methanol:acetone and stained using lamin B2 primary antibod-
ies and FITC-conjugated secondary antibodies were scored by
eye using an Olympus BX-41 fluorescence microscope with an
UPlanFl 9100/1.30 objective lens (Olympus Corporation,
Japan). The scoring patterns used for the analysis were rim,
rim and speckles, speckles, and negative. Scoring results for the
treatments are shown as a FTI-277 (2.5 lM for 24 h),
b pravastatin (1 lM for 24 h), c zoledronic acid (1 lM for
24 h), d rapamycin (10 nM for 24 h), e insulin-like growth
factor 1 (50.0 ng ml-1 for 24 h), f N-acetyl-L-cysteine (20 lM
for 1 h), g FTI-277 and GGTI-2133 (both 2.5 lM for 24 h),
h pravastatin and zoledronic acid (both 1 lM for 24 h) and i)
FTI-277 (2.5 lM for 24 h), pravastatin and zoledronic acid
(both 1 lM for 24 h). Error bars are SEM
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territory positions are restored in HGPS cells partic-
ularly treated with these drugs (Bikkul et al. 2018),
since they restore a more normal lamin A distribution
and presumably allow lamina associated domains
(LADs) to be tethered at the nuclear envelope
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these drugs that prevent the farnesylation of progerin
also lead to accumulations of prelamin A at the nuclear
envelope (as also shown by Adam et al. 2013) and in
the nucleoplasm as speckles. Indeed, all these drugs
singularly, and in combination, led to rim and internal
speckle distributions—with strong rim staining seen
for treatments with FTI, zoledronic acid and all the
combinations (FTI ? GGTI, PZ, FPZ). Our study
extends this by showing that other inhibitors of other
signalling proteins in the mevalonate pathway, such as
pravastatin and zoledronic acid, also lead to cells
exhibiting accumulation of prelamin A at the nuclear
rim, but to a lesser extent. Importantly, prelamin A is
known to be a toxic protein if left uncleaved and
embedded in the nuclear rim (Fong et al. 2006;
Dominici et al. 2009; Davies et al. 2011). Pravastatin
performed the best of the drugs affecting farnesyla-
tion, since it only produced a weak rim of prelamin A
staining. Assessing this study and our other recent
study (Bikkul et al. 2018) in combination it seems that
the presence of prelamin A at the nuclear envelope
does not prevent LAD binding, since gene-poor
chromosomes are located to the nuclear envelope
after drug treatments.
Much is being made of rapamycin as a new
treatment for HGPS and even normal ageing (Men-
delsohn and Larrick 2012). In this study rapamycin
treatment does increase the proportion of progerin
negative cells but does not alter the fraction of cells
with internal progerin speckles. We also saw a
reduction in prelamin A with rapamycin probably
due to the activation of autophagic pathways and
degradation of prelamin A that have been previously
been reported upon treatment with rapamycin (Cao
et al. 2011). A drug that affects both the progerin
populations would seem to be a more sensible choice,
that did not have adverse effects elsewhere—that drug
could be NAC with respect to this study since it has a
positive effect on both progerin populations and does
not have deleterious effects on other lamin distribu-
tions such as accumulation of prelamin A; whereas
zoledronic acid does reduce both progerin pools but
does not restore normal lamin A staining.
HGPS cells also display abnormal distributions of
lamin B2. Lamin B2 was observed located away from
the nuclear envelope as speckles within the nucleo-
plasm. This implies that lamin B2 requires lamin A to
be localised at the nuclear envelope or that its journey
is impeded by progerin. As opposed to lamin A/C and
lamin B1, very few studies have been conducted
studying lamin B2 localisation following drug treat-
ments in HGPS fibroblasts. However, the study by
Adam et al. (2013) saw that there was an increase in
lamin B2 speckles due to unfarnesylated lamin B2
accumulating in the nucleoplasm. The results obtained
in our study however suggest that untreated HGPS
fibroblasts already have a high proportion of lamin B2
speckles in the nucleoplasm compared to control
fibroblasts, and that drug treatments were able to
increase rim staining whilst at the same time, reduce
internal speckles, bringing the HGPS cells towards
that of control cells.
Wild-type fibroblasts used in this study do not
exhibit prelamin A at the nuclear rim. In this study
regulators of the mTOR pathway, such as rapamycin
and IGF-1 do not induce HGPS cells to exhibit
prelamin A accumulation at the nuclear membrane.
There is a significant reduction in nuclear speckles,
with no accumulation of prelamin A at the nuclear rim.
These data indicate that drugs that are able to
manipulate the mTOR pathway may be beneficial in
terms of treatment of HGPS. Furthermore, we also
revealed that suggested potential drug treatments
IGF1 and NAC also have a positive effect on HGPS
cells without producing a concentration of prelamin A
at the nuclear rim.
The specific lamin A antibody used during this
study targets residues 598–611 at the C terminus of
lamin A. In this study the antibody exhibits very weak
or negative staining in untreated A01972 fibroblasts,
indicating that very little full length lamin A protein is
actually produced in these cells. The fact that HGPS
fibroblasts show a large proportion of negative stain-
ing is reflected in previous studies that have used the
same specific lamin A antibody to immunostain HGPS
fibroblast cell lines (Bridger and Kill 2004). Instead of
producing lamin A, AG01972 produces progerin,
which forms aggregates in the nucleoplasm as well
as accumulating at the nuclear envelope. The HGPS
cells must also produce lamin C since the anti-lamin
A/C staining is evident in these cells at the nuclear rim.
Drug treatments such as FTI elevate the amount of
lamin A at the nuclear envelope, and at the same time
lead to a reduction of progerin at the nuclear envelope.
However, the blocking of farnesylation by FTI treat-
ments does not lead to a clearance of progerin protein
from the nucleoplasm. This relocation of progerin in
response to FTI treatment is in strong agreement with
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previous work carried out using in vitro mouse models
(Yang et al. 2005). In addition, our study shows that
pravastatin, another inhibitor of the mevalonate path-
way, can bring about similar effects as FTI treatment
in human cells.
The drugs may redistribute lamin A/C from nucle-
oplasmic speckles to the nuclear membrane, reduce
nucleoplasmic speckles themselves or reduce their
association with lamin A/C. It is known that progerin
forms insoluble aggregates in the nucleoplasm (Cao
et al. 2011). It has previously been described that
blocking farnesylation of lamin A can lead to the
redistribution of the protein away from the inner
nuclear membrane (Wang et al. 2012), which may
explain why FTI-277, pravastatin and zoledronic acid
did not completely rescue nucleoplasmic foci back to
control levels. Drugs that do not manipulate farnesy-
lation performed better.
In conclusion, the results of this study have
potentially far-reaching implications for the treatment
of sufferers with HGPS since the drugs being used in
clinical trial are a FTI—lonafarnib, and a rapalogue—
everolimus.
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